Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.75 EUR | +0.07% | +0.07% | +99.26% |
Apr. 11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
Apr. 11 | Trending : Novartis Begins Tender Offer for MorphoSys Shares | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+99.26% | 2.73B | B- | ||
+1.12% | 42.59B | B | ||
+6.77% | 40.65B | B- | ||
+45.26% | 40.57B | A | ||
-11.96% | 26.77B | C | ||
+6.01% | 24.81B | B- | ||
-24.92% | 18.17B | B | ||
-3.63% | 11.7B | C+ | ||
+27.16% | 12.05B | C+ | ||
+7.30% | 11.1B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MOR Stock
- Ratings MorphoSys AG